Download PDF
Exp Clin Endocrinol Diabetes 1988; 91(2): 217-222
DOI: 10.1055/s-0029-1210748
Original

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Coexistence of Somatostatin-immunoreactivity in an Adrenal Pheochromocytoma and a Thyroid Medullary Carcinoma (Sipple syndrome)

N. Bethge, S. Ahuja, F. Diel, K. H. Usadel*
  • Institut für Pathologie, Strahlenklinik und Poliklinik, Universitätsklinikum Steglitz, Freie Universität Berlin, Universität Heidelberg
  • * Zentrum der Inneren Medizin der Johann-Wolfgang-Goethe-Universität, Abteilung für Endokrinologie, Frankfurt am Main, II. Medizinische Klinik, Klinikum Mannheim, Universität BRD
Further Information

Publication History

1987

Publication Date:
16 July 2009 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The presence of somatostatin-immunoreactivity in tumor tissue of adrenal pheochromocytoma and thyroid medullary carcinoma identified by peroxidase-antiperoxidase technique is reported in one case of Sipple syndrome. This patient was found to have a high concentration of somatostatin-immunoreactivity in the peripheral blood (40 ng/l, normal 0-20 ng/l). After removal of the tumors, the plasma somatostatin-immunoreactivity fell within normal range (12.5 ng/l).

This seems to be the first report of Sipple syndrome that produces somatostatin-immunoreactivity in both: pheochromocytoma and thyroid medullary carcinoma.

Key words

Sipple syndrome - Somatostatin - Pheochromocytoma - Thyroid medullary carcinoma